Drug Profile
Desirudin
Alternative Names: CGP 39393; Desulfatohirudin recombinant; Iprivask; r-Hirudin; RevascLatest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Novartis
- Developer Canyon Pharmaceuticals
- Class Anticoagulants; Antithrombotics; Hirudins; Recombinant proteins
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Deep vein thrombosis
- No development reported Thrombosis
Most Recent Events
- 13 Jul 2018 Valeant Pharmaceuticals International is now called Bausch Health Companies
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Thrombosis(Prevention) in Unknown (IV)
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Thrombosis(Prevention) in USA (SC)